Research & Publications

A curated library of technical references, articles, and presentations that highlight the science informing our CADASIL-first development strategy and broader vascular-degeneration research.

  • 1.         Lam JD, Oh DJ, Wong LL, Amarnani D, Park-Windhol C, Sanchez AV, Cardona-Velez J, McGuone D, Stemmer-Rachamimov AO, Eliott D, Bielenberg DR, van Zyl T, Shen L, Gai X, D'Amore PA, Kim LA, Arboleda-Velasquez JF. Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis. Diabetes 2017.

    2.         Gonzalez-Buendia L, Delgado-Tirado S, An M, O'Hare M, Amarnani D, A B Whitmore H, Zhao G, Ruiz-Moreno JM, Arboleda-Velasquez JF, Kim LA. Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. The American journal of pathology 2021;191:418-424.

    3.         Delgado-Tirado S, Gonzalez-Buendia L, An M, Amarnani D, Isaacs-Bernal D, Whitmore H, Arevalo-Alquichire S, Leyton-Cifuentes D, Ruiz-Moreno JM, Arboleda-Velasquez JF, Kim LA. Topical Nanoemulsion of an Runt-related Transcription Factor 1 Inhibitor for the Treatment of Pathologic Ocular Angiogenesis. Ophthalmology Science 2022;2.

    4.         Delgado-Tirado S, Amarnani D, Zhao G, Rossin EJ, Eliott D, Miller JB, Greene WA, Ramos L, Arevalo-Alquichire S, Leyton-Cifuentes D, Gonzalez-Buendia L, Isaacs-Bernal D, Whitmore HAB, Chmielewska N, Duffy BV, Kim E, Wang HC, Ruiz-Moreno JM, Kim LA, Arboleda-Velasquez JF. Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. Sci Rep 2020;10:20554.

    5.         O'Hare M, Amarnani D, Whitmore HAB, An M, Marino C, Ramos L, Delgado-Tirado S, Hu X, Chmielewska N, Chandrahas A, Fitzek A, Heinrich F, Steurer S, Ondruschka B, Glatzel M, Krasemann S, Sepulveda-Falla D, Lagares D, Pedron J, Bushweller JH, Liu P, Arboleda-Velasquez JF, Kim LA. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators. The American journal of pathology 2021;191:1193-1208.

    6.         Clifford KA, Levine AA, Enright DE, Neumann PJ, Chambers JD. Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower Costs. Health Aff (Millwood) 2024;43:1546-1552.

    7.         Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 1995;172:1246-1252.